DK0871440T3 - Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister - Google Patents

Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister

Info

Publication number
DK0871440T3
DK0871440T3 DK96941518T DK96941518T DK0871440T3 DK 0871440 T3 DK0871440 T3 DK 0871440T3 DK 96941518 T DK96941518 T DK 96941518T DK 96941518 T DK96941518 T DK 96941518T DK 0871440 T3 DK0871440 T3 DK 0871440T3
Authority
DK
Denmark
Prior art keywords
schizophrenia
negative
treatment
cognitive symptoms
glycine uptake
Prior art date
Application number
DK96941518T
Other languages
English (en)
Inventor
Daniel C Javitt
Original Assignee
Daniel C Javitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21731199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0871440(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daniel C Javitt filed Critical Daniel C Javitt
Application granted granted Critical
Publication of DK0871440T3 publication Critical patent/DK0871440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK96941518T 1995-12-07 1996-12-05 Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister DK0871440T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US836195P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
DK0871440T3 true DK0871440T3 (da) 2006-07-10

Family

ID=21731199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941518T DK0871440T3 (da) 1995-12-07 1996-12-05 Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister

Country Status (10)

Country Link
US (3) US5854286A (da)
EP (1) EP0871440B1 (da)
JP (3) JP2000501707A (da)
AT (1) ATE320804T1 (da)
DE (1) DE69635959T2 (da)
DK (1) DK0871440T3 (da)
ES (1) ES2260773T3 (da)
IL (1) IL124536A (da)
PT (1) PT871440E (da)
WO (2) WO1997020553A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6001854A (en) * 1996-05-31 1999-12-14 Allelix Neuroscience Inc. Pharmaceutical for treating of neurological and neuropsychiatric disorders
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6416975B1 (en) * 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
WO2000062812A1 (en) * 1999-04-20 2000-10-26 Advocare International Llc Nutritional composition for improved cognitive performance
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
US6667336B2 (en) 2001-02-16 2003-12-23 Nps Allelix Corp. GlyT-1 inhibitors
US20020187544A1 (en) * 2001-04-05 2002-12-12 Wisconsin Alumni Research Foundation Uropathogenic E. coli D-serine detoxification operon
WO2004005935A1 (ja) * 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
FR2843590B1 (fr) * 2002-08-14 2007-10-05 Prestwick Scient Capital Inc Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
ATE407117T1 (de) * 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
IL154318A (en) * 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
JP2006524642A (ja) 2003-04-30 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 芳香族オキシフェニルおよび芳香族スルファニルフェニル誘導体
CA2536275A1 (en) * 2003-08-21 2005-03-03 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
CA2547652A1 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
EP1781279A2 (de) * 2004-06-11 2007-05-09 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
EP3701945A1 (en) 2004-08-09 2020-09-02 Enrique Melendez Hevia Glycine composition for use in the prevention and/or treatment of cancer in a humand in need of promoting the synthesis of collagen
WO2006066121A2 (en) * 2004-12-16 2006-06-22 Janssen Pharmaceutica N.V. Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof
TW200820963A (en) * 2006-07-28 2008-05-16 Xenoport Inc Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
NO2200610T3 (da) * 2007-09-21 2018-06-09
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2010053976A2 (en) * 2008-11-04 2010-05-14 Mclean Hospital Corporation Drug-enhanced neurofeedback
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2816609A1 (en) * 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN107848972B (zh) 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Composition and method for treatment or depression and psychosis in humans
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
CN114805139B (zh) 2018-01-10 2023-10-20 凯瑞康宁生物工程（武汉）有限公司 氯胺酮的前药、其组合物和用途
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
EP4061387A1 (en) * 2019-11-18 2022-09-28 Société des Produits Nestlé S.A. Compositions and methods for glutathione enhancement for use in brain health
TWI844074B (zh) 2021-08-13 2024-06-01 凱瑞康寧生技股份有限公司 氯胺酮衍生物之醫藥組成物及口服劑型

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5179085A (en) * 1989-03-15 1993-01-12 Warner-Lambert Company N-substituted α-amino acids and derivatives thereof having pharmaceutical activity
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
WO1993010228A1 (en) 1991-11-12 1993-05-27 Synaptic Pharmaceutical Corporation Dna encoding a glycine transporter and uses thereof
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina

Also Published As

Publication number Publication date
US6162827A (en) 2000-12-19
DE69635959D1 (de) 2006-05-11
IL124536A (en) 2001-03-19
ES2260773T3 (es) 2006-11-01
US5837730A (en) 1998-11-17
EP0871440B1 (en) 2006-03-22
JP2013056918A (ja) 2013-03-28
JP2009167205A (ja) 2009-07-30
DE69635959T2 (de) 2006-12-07
WO1997020553A1 (en) 1997-06-12
EP0871440A4 (en) 1999-01-20
WO1997020552A1 (en) 1997-06-12
PT871440E (pt) 2006-07-31
JP5363152B2 (ja) 2013-12-11
IL124536A0 (en) 1998-12-06
ATE320804T1 (de) 2006-04-15
JP2000501707A (ja) 2000-02-15
EP0871440A1 (en) 1998-10-21
US5854286A (en) 1998-12-29

Similar Documents

Publication Publication Date Title
PT871440E (pt) Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
NO911624L (no) Farmasoeytiske forbindelser.
TR199900308T2 (xx) Tiyenopirimidinler
TW287160B (da)
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DE3683528D1 (de) Tetrapyrrol-therapiemittel.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
HU9602721D0 (en) Use of serotonin antagonists (5ht3) for treating fibromyalgia
IE890518L (en) Tetrazole excitatory amino acid receptor antagonists
IE852596L (en) Peptides active on the cns
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
EP0688319A4 (en) 4-HYDROXY-3-NITRO-1,2-DIHYDROCHINOLIN-2-ONE AND THE USE THEREOF AS EXCITATIVE AMINO ACIDS AND GLYCINE RECEPTOR ANTAGONISTS
DE69412178D1 (de) Apparat zur Behandlung von Lagen
NZ324615A (en) Method for treating autism using olanzapine
DK366380A (da) Anvendelsen af grp og salte deraf
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
CA2239624A1 (en) Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
EP0210099A3 (en) Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease